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only about one-ﬁfth fulﬁl the speciﬁc criteria required for CFS [5].
Clinical similarities apart, there are biological differences between
the two; for example, cerebrospinal ﬂuid levels of substance P are
elevated in FMS but not in CFS patients [6], and cardiovascular
responses to postural challenge are characteristic of many CFS
patients but are not apparent in those with FMS [7].
Our group has previously demonstrated that CFS patients have
a signiﬁcantly increased microcirculatory blood ﬂow response to
the endothelium-dependent vasodilator acetylcholine (ACh) [8] but
not to the endothelium-independent vasodilator sodium nitroprus-
side (SNP)—a unique phenomenon that we believe may be related
to a disturbance of endothelial acetylcholinesterase expression in
these patients [9]. Similar experiments carried out by us on patients
with FMS [10] and matched control subjects failed to demonstrate
any signiﬁcant difference in either the ACh or SNP responses, nor
did these patients show increased baseline vasoconstriction, but the
FMS patients did have a signiﬁcantly elevated resting blood
pressure compared with their matched controls.
As part of an investigation into speciﬁc vascular risk factors in
CFS, we have recently completed a study in our Vascular Diseases
Research Unit on 47 patients who, on clinical examination,
fulﬁlled the Centre for Disease Control 1994 criteria for CFS
[11], and 34 age- and sex-matched healthy controls. The local ethics
committee approved the study and all subjects gave written,
informed consent. Supine blood pressure measurements were
obtained after a standard rest period of 20min. ET-1 levels were
measured from a morning blood sample, collected in EDTA
(ethylenediamine tetraacetate), kept on ice and then centrifuged
at 4C within 5min. Plasma was separated, aliquoted and stored at
–70C until assayed for ET-1 levels by ELISA (enzyme-linked
immunosorbent assay) (R&D Systems, Oxford, UK).
No differences in plasma ET-1 levels were found between CFS
patients and their control group (P¼ 0.30, unpaired t test). CFS
patients had a mean ET-1 level of 0.49 pg/ml (range 0.11–1.02) and
the control group had a mean ET-1 level of 0.44 pg/ml (range
0.16–0.92). We also found no differences in blood pressure between
CFS patients and control subjects. The mean and range for systolic
blood pressure were 125mmHg (90–198) in CFS patients and
123mmHg (100–180) in controls (P¼ 0.50); for diastolic blood
pressure the results for CFS patients and control subjects were
74mmHg (50–108) and 72mmHg (50–88) respectively (P¼ 0.36).
Taken together, these experimental data challenge the concept
that CFS and FMS are part of the same spectrum of illness.
Normal ET-1 levels in CFS patients in conjunction with an
enhanced endothelial response to ACh may predispose these
patients to abnormal cardiovascular responses to orthostatic
challenge. While there have been reports of impaired activation of
the hypothalamic–pituitary–adrenal (HPA) axis in both CFS and
FMS patients that is clearly dissimilar to that seen in depression
[12], caution is required about assuming that FMS and CFS are
aetiologically analogous disorders of the stress response axis.
Our results show no elevation of ET-1 in CFS, in contrast to the
data of Pache et al.
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Reply
SIR, we appreciate the comments by Dr Kennedy and colleagues
regarding our report [1] about plasma endothelin-1 levels in
ﬁbromyalgia syndrome. The aim of our study was to measure
endothelin-1 (ET-1) plasma levels in patients with ﬁbromyalgia
syndrome (FMS), and to compare the results with those for
healthy controls matched for sex and age. Using a speciﬁc
radioimmunoassay [2], we found plasma ET-1 levels to be
signiﬁcantly increased in FMS patients when compared with
controls (2.74 0.76 pg/ml, range 1.68–3.95 vs 1.4 0.23 pg/ml,
range 0.9–1.86; P<0.0001).
Dr Kennedy and colleagues measured plasma ET-1 levels in
patients with chronic fatigue syndrome (CFS) by means of ELISA
and found the ET-1 levels to be unaltered in their patients. They
conclude that ‘these data challenge the concept that CFS and FMS
are part of the same spectrum of illness’. Their ﬁnding is indeed
interesting, but it remains unclear to us why these data are ‘in
contrast to’ our data, as we measured plasma ET-1 levels in FMS
and not in CFS patients. Moreover, in the Introduction of our
report we pointed out a clinical, but not an aetiological, overlap
between FMS and CFS.
The results of Dr Kennedy and colleagues lend additional
support to the hypothesis that FMS and CFS are aetiologically
distinct. However, further research in this ﬁeld is necessary
before ﬁrm conclusions can be drawn.
Letters to the Editor 253
Rheumatology Vol. 43 No. 2 British Society for Rheumatology 2004; all rights reserved
M. PACHE, T. KUBE, J. FLAMMER
University Eye Clinic Basel, Mittlere Strasse 91, P.O. Box,
CH-4012 Basel, Switzerland
Accepted 20 June 2003
Correspondence to: J. Flammer. E-mail: Josef.Flammer@
uhbs.ch
1. Pache M, Ochs J, Genth E, Mierau R, Kube T, Flammer J.
Increased plasma endothelin-1 levels in ﬁbromyalgia syndrome.
Rheumatology 2003;42:493–4.
2. Moreau P, Takase H, Kung CF, Shaw S, Luscher TF. Blood
pressure and vascular effects of endothelin blockade in chronic nitric
oxide-deﬁcient hypertension. Hypertension 1997;29:763–9.
Rheumatology 2004;43:254
doi:10.1093/rheumatology/keg463
Systemic juvenile idiopathic arthritis, Kikuchi’s disease
and haemophagocytic lymphohistiocytosis
SIR, I read with interest the case report of a 1-yr-old girl with
systemic juvenile idiopathic arthritis and Kikuchi’s disease, who
later developed haemophagocytic lymphohistiocytosis (HLH),
and its successful management [1]. Diagnostic criteria for HLH
were published in 1991 [2]. The diagnosis of HLH requires the
presence of all ﬁve criteria (fever >38.5C for 7 or more days,
palpable splenomegaly, cytopenia involving two or more cell
lines, hypertriglyceridaemia or hypoﬁbrinogenaemia and haemo-
phagocytosis). The case reported by Ramanan et al. [1] satisﬁes
the diagnostic criteria.
In a recent study of 122 children with HLH enrolled from 11
countries, the rate of parental consanguinity was 24% and there
was a positive family history in 49% of cases [3]. Ramanan et al.
have not commented on the parental consanguinity and the family
history of their patient.
The prognosis of HLH has improved signiﬁcantly since the
advent of the HLH-94 protocol from the Histiocyte Society [3].
The protocol includes induction with dexamethasone and etopo-
side and intrathecal methotrexate in selected cases, followed by
continuous treatment with cyclosporin along with pulses of
dexamethasone and etoposide for 1 yr. However, haematopoietic
cell transplantation appears to provide the best cure rate, of about
60% [4]. The 40-page HLH-94 protocol can be obtained from
the Histiocytosis Association of America through their website
(http://www.histio.org/society/protocols/trials-protocols.shtml).
However, treating physicians and potential patients must be
registered before the protocol can be released.
Epstein–Barr virus and parvovirus B19 infections can be
associated with both HLH and Kikuchi’s disease [5–7].
Ramanan et al. do not mention whether their patient was tested
for these infections.
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SIR, We thank Dr Jawad for his comments and his interest in our
paper [1]. To address the issues raised by the author, there was no
family history of haemophagocytic lymphohistiocytosis (HLH) or
of consanguinity. We did do serology for Epstein–Barr virus (EBV)
and parvovirus, both of which were negative (we mentioned in our
paper that the viral serology was negative, although we did not
specify the viruses checked).
As for his comments on the diagnostic criteria, these are beset
with problems. The criteria were designed primarily for the
diagnosis of primary HLH, but many clinicians in practice use
the criteria for secondary HLH and for HLH associated with
rheumatic disease. Henter et al. [2], in their criteria, acknowledge
the fact that not all patients will fulﬁl the criteria and that clinical
decisions regarding therapy need to be made even when patients do
not satisfy the diagnostic criteria.
There are certain problems with the existing criteria. Low
haemoglobin concentration, raised white cell count and raised
platelet count are characteristic of active systemic disease in
systemic onset juvenile idiopathic arthritis (SoJIA). Hence, relative
cytopenia may enable earlier diagnosis of HLH compared with the
absolute cytopenia in the present criteria.
One of the major problems with the existing criteria for HLH is
the need for tissue demonstration of haemophagocytosis. It is well
recognized that bone marrow aspirate or biopsy may not always
show haemophagocytosis; furthermore, haemophagocytosis is not
always demonstrable at onset [3, 4]. In one series of 27 children
with primary HLH, autopsy studies revealed haemophagocytosis
in the bone marrow in only 39% (9/23). On the contrary, 71 and
74% showed haemophagocytosis in the spleen and lymph nodes
respectively [4]. Whilst this demonstrates that biopsies of the spleen
and lymph nodes have higher yields, they constitute a much greater
risk in the face of active coagulopathy. There is a need for criteria
that take these difﬁculties into account, yet provide a robust
framework for early diagnosis and treatment.
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